UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study

Annals of oncology, 2022-09, Vol.33 (9), p.929-938

2022

Volltextzugriff (PDF)

Adjuvant radiotherapy for extremity and trunk wall atypical lipomatous tumor/well-differentiated LPS (ALT/WD-LPS): a French Sarcoma Group (GSF-GETO) study

Annals of oncology, 2014-09, Vol.25 (9), p.1854-1860

2014

Volltextzugriff (PDF)

The complex balance of PI3K inhibition

Annals of oncology, 2021-02, Vol.32 (2), p.127-128

2021

Volltextzugriff (PDF)

Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials?

Annals of oncology, 2019-11, Vol.30 (11), p.1751-1759

2019

Volltextzugriff (PDF)

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages

Annals of oncology, 2019-08, Vol.30 (8), p.1381-1392

2019

Volltextzugriff (PDF)

Patients’ selection and trial matching in early-phase oncology clinical trials

Critical reviews in oncology/hematology, 2024-04, Vol.196, p.104307-104307, Article 104307

2024

Volltextzugriff (PDF)

1030TiP An open-label multicenter phase Ib study of AN0025, a selective inhibitor of the prostaglandin E2 receptor-type-4 receptor, in combination with pembrolizumab in patients with advanced solid tumors

Annals of oncology, 2021-09, Vol.32, p.S862-S863

2021

Volltextzugriff (PDF)

58 (PB046): Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): the ReFocus study

European journal of cancer (1990), 2024-10, Vol.211, p.114585, Article 114585

2024

Volltextzugriff (PDF)

Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study

Gynecologic oncology, 2022-08, Vol.166 (2), p.245-253

2022

Volltextzugriff (PDF)

113P Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial

Annals of oncology, 2022-09, Vol.33, p.S589-S590

2022

Volltextzugriff (PDF)

486P Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas

Annals of oncology, 2021-09, Vol.32, p.S572-S573

2021

Volltextzugriff (PDF)

MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S117-S118

2023

Volltextzugriff (PDF)

1494P Regomune - a phase II study of regorafenib + avelumab in solid tumors: Results of the soft tissue sarcoma (STS) cohort

Annals of oncology, 2022-09, Vol.33, p.S1230

2022

Volltextzugriff (PDF)

392P Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas

Annals of oncology, 2022-09, Vol.33, p.S716

2022

Volltextzugriff (PDF)

546P Pembrolizumab for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial cancer: Long-term follow-up results from KEYNOTE-158

Annals of oncology, 2022-09, Vol.33, p.S796-S797

2022

Volltextzugriff (PDF)

983P Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor

Annals of oncology, 2021-09, Vol.32, p.S841-S842

2021

Volltextzugriff (PDF)

797P Health-related quality of life (HRQoL) with pembrolizumab (pembro) monotherapy in patients (pts) with previously treated advanced microsatellite instability high (MSI-H) endometrial cancer: Results from KEYNOTE-158

Annals of oncology, 2021-09, Vol.32, p.S760-S761

2021

Volltextzugriff (PDF)

1534P Patterns of care and outcomes of NTRK-fusion positive sarcomas: A retrospective and prospective cases series

Annals of oncology, 2021-09, Vol.32, p.S1117-S1117

2021

Volltextzugriff (PDF)

795MO Pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): Updated results from KEYNOTE-158

Annals of oncology, 2021-09, Vol.32, p.S730-S731

2021

Volltextzugriff (PDF)

456MO METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors

Annals of oncology, 2022-09, Vol.33, p.S746-S747

2022

Volltextzugriff (PDF)

LBA12 Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial

Annals of oncology, 2022-09, Vol.33, p.S1381

2022

Volltextzugriff (PDF)

480P CATRIPCA – A phase I of pembrolizumab (P) combined with Xevinapant (Debio 1143, (X)) in patients (pts) with non MSI-high advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) or colorectal cancer (CRC)

Annals of oncology, 2022-09, Vol.33, p.S759

2022

Volltextzugriff (PDF)

1654P Updated ARROW data: Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC)

Annals of oncology, 2022-09, Vol.33, p.S1298-S1299

2022

Volltextzugriff (PDF)

Cell lineage context and type of genomic alteration predict for the therapeutic relevance of tyrosine kinase inhibitors in human cancers

Annals of oncology, 2019-11, Vol.30, p.vii23

2019

Volltextzugriff (PDF)

115MO Long-term efficacy, tolerability and overall survival in patients (pts) with unresectable or metastatic (U/M) PDGFRA D842V-mutant gastrointestinal stromal tumour (GIST) treated with avapritinib: NAVIGATOR phase I trial update

Annals of oncology, 2020-11, Vol.31, p.S1287-S1288

2020

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(35)

Sprache

Englisch
(33)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(9)
Oncology
(9)
Science & Technology
(9)
Humans
(6)
Adult
(4)
Aged
(4)
Female
(4)
Middle Aged
(4)
Treatment Outcome
(4)
Male
(3)
Aged, 80 And Over
(2)
Antineoplastic Agents
(2)
Antineoplastic Agents - Therapeutic Use
(2)
Biological And Medical Sciences
(2)
Cancer
(2)
Dose-Response Relationship, Drug
(2)
Immunotherapy
(2)
Maximum Tolerated Dose
(2)
Medical Sciences
(2)
Mismatch Repair Deficiency
(2)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

2 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(28)
Gastroentérologie Clinique Et Biologique
(2)
Critical Reviews In Oncology/hematology
(1)
Drugs Of The Future
(1)
European Journal Of Cancer
(1)
Gynecologic Oncology
(1)
Journal Of Thoracic Oncology
(1)

2 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study

Adjuvant radiotherapy for extremity and trunk wall atypical lipomatous tumor/well-differentiated LPS (ALT/WD-LPS): a French Sarcoma Group (GSF-GETO) study

The complex balance of PI3K inhibition

Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials?

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages

Patients’ selection and trial matching in early-phase oncology clinical trials

1030TiP An open-label multicenter phase Ib study of AN0025, a selective inhibitor of the prostaglandin E2 receptor-type-4 receptor, in combination with pembrolizumab in patients with advanced solid tumors

58 (PB046): Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): the ReFocus study

Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study

113P Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial

486P Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas

MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors

1494P Regomune - a phase II study of regorafenib + avelumab in solid tumors: Results of the soft tissue sarcoma (STS) cohort

392P Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas

546P Pembrolizumab for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial cancer: Long-term follow-up results from KEYNOTE-158

983P Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor

797P Health-related quality of life (HRQoL) with pembrolizumab (pembro) monotherapy in patients (pts) with previously treated advanced microsatellite instability high (MSI-H) endometrial cancer: Results from KEYNOTE-158

1534P Patterns of care and outcomes of NTRK-fusion positive sarcomas: A retrospective and prospective cases series

795MO Pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): Updated results from KEYNOTE-158

456MO METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors

LBA12 Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial

480P CATRIPCA – A phase I of pembrolizumab (P) combined with Xevinapant (Debio 1143, (X)) in patients (pts) with non MSI-high advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) or colorectal cancer (CRC)

1654P Updated ARROW data: Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC)

Cell lineage context and type of genomic alteration predict for the therapeutic relevance of tyrosine kinase inhibitors in human cancers

115MO Long-term efficacy, tolerability and overall survival in patients (pts) with unresectable or metastatic (U/M) PDGFRA D842V-mutant gastrointestinal stromal tumour (GIST) treated with avapritinib: NAVIGATOR phase I trial update

Suchergebnisse filtern